Skip to main content
SpringerLink
Log in

Mood Disorders in Patients with Epilepsy

Epidemiology and Management

  • Therapy In Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and the risk of exacerbating seizures with antidepressant treatment. Bipolar disorder is not described as occurring with a higher than expected frequency in the population with epilepsy, but high rates of depression and suicide are well recognised, highlighting the need for more emphasis on antidepressive treatment in this group of at-risk patients.

Neurological factors, including site and lateralisation of seizure focus, may be important for the development of depression, with left-sided seizure foci having a higher association with depressive symptoms. Forced normalisation may be a factor in the paradoxical onset of depression in patients with epilepsy whose seizures suddenly become well controlled by anti-seizure treatment. Lowering of folic acid levels by some antiepileptic drugs (AEDs) may also influence the expression of depression in patients with epilepsy.

New AEDs continue to emerge as beneficial treatments themselves for mood disorders, with lamotrigine, gabapentin and, to a lesser extent, topiramate having clinical trials data to support their use in patients with bipolar disease. Similar positive data are available for vagal nerve stimulation. Mood effects of AEDs can be complicated, however, as many of these drugs (e.g. tiagabine) have also been reported to cause depression as an adverse effect. Electroconvulsive therapy in depressed patients with epilepsy requires special consideration.The selective serotonin reuptake inhibitors (SSRIs) and antidepressants that act at multiple receptors (e.g. nefazodone, venlafaxine) are the most appropriate treatments for depressed patients with epilepsy. Among these agents, citalopram has a low risk of interactions with AEDs. Bupropion, clomipramine and maprotiline are associated with a greater risk of seizures compared with other antidepressants and consequently should be used with caution in the treatment of depression in patients with epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Hermann BP, Seidenberg M, Bell M. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 2000; 41 Suppl. 2: S31–41

    Article  PubMed  Google Scholar 

  2. Edeh J, Toone BK, Corney RH. Epilepsy, psychiatric morbidity, and social dysfunction in general practice. Comparison between clinic patients and clinic nonattenders. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3: 180–92

    Google Scholar 

  3. Edeh J, Toone B. Relationship between interictal psychopathology and type of epilepsy. Results of a survey in general practice. Br J Psychiatry 1987; 151: 95–101

    Article  PubMed  CAS  Google Scholar 

  4. Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. community study. Epilepsia 1996; 37: 148–61

    Article  PubMed  CAS  Google Scholar 

  5. Victoroff JI, Benson DF, Engel Jr J, et al. Interictal depression in patients with medically intractable complex partial seizures: electroencephalography and cerebral metabolic correlates [abstract]. Ann Neurol 1990; 28: 221

    Google Scholar 

  6. Indaco A, Carrieri PB, Nappi C, et al. Interictal depression in epilepsy. Epilepsy Res 1992; 12: 45–50

    Article  PubMed  CAS  Google Scholar 

  7. Victoroff JI, Benson DF, Grafton ST, et al. Depression in complex partial seizures. Electroencephalography and cerebral metabolic correlates. Arch Neurol 1994; 51: 155–63

    Article  PubMed  CAS  Google Scholar 

  8. Robertson MM, Channon S, Baker J. Depressive symptomatology in a general hospital sample of outpatients with temporal lobe epilepsy: a controlled study. Epilepsia 1994; 35: 771–7

    Article  PubMed  CAS  Google Scholar 

  9. Boyd JH, Weissman MM. Epidemiology. In: Paykel ES, editor. Handbook of affective disorders. New York: The Guilford Press, 1982: 25

    Google Scholar 

  10. Blumer D. Postictal depression: significance for the neurobehavioral disorder of epilepsy. J Epilepsy 1992; 5: 214–9

    Article  Google Scholar 

  11. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia 1999; 40 Suppl. 10: S21–47

    Article  PubMed  CAS  Google Scholar 

  12. Lim J, Yagnik P, Schraeder P, et al. Ictal catatonia as a manifestation of nonconvulsive status epilepticus. J Neurol Neurosurg Psychiatry 1986; 49: 833–6

    Article  PubMed  CAS  Google Scholar 

  13. Betts TA. Neuropsychiatry. In: Laidlaw J, Richens A, Chadwick D, editors. A textbook of epilepsy. 4th ed. Edinburgh: Churchill-Livingston, 1993: 397–458

    Google Scholar 

  14. Mendez MF, Doss RC. Ictal and psychiatric aspects of suicide in epileptic patients. Int J Psychiatry Med 1992; 22: 231–7

    Article  PubMed  CAS  Google Scholar 

  15. Wiegartz P, Seidenberg M, Woodard A, et al. Co-morbid psychiatrie disorder in chronic epilepsy: recognition and etiology of depression. Neurology 1999; 53(5 Suppl. 2): S3–8

    PubMed  CAS  Google Scholar 

  16. Reynolds EH. Interictal psychiatric disorders. Adv Neurol 1991; 55: 47–57

    PubMed  CAS  Google Scholar 

  17. Robertson MM. Affect and mood in epilepsy: an overview with a focus on depression. Acta Neurol Scand 1992; 86: 127–32

    Article  Google Scholar 

  18. Barraclough B. The suicide rate of epilepsy. Acta Psychiatry Scand 1987; 76: 339–45

    Article  CAS  Google Scholar 

  19. Kanner AM, Nieto JC. Depressive disorders in epilepsy. Neurology 1999; 53(5 Suppl. 2): S26–32

    PubMed  CAS  Google Scholar 

  20. Manchanda R, Schaefer B, McLachlan RS, et al. Relationship of site of seizure focus to psychiatric morbidity. J Epilepsy 1995; 8: 23–8

    Article  Google Scholar 

  21. Herman BP, Seidenberg M, Haitiner A, et al. Mood state in unilateral temporal lobe epilepsy. Biol Psychiatry 1991; 30: 1205–18

    Article  Google Scholar 

  22. Bromfield EB, Alshuler L, Leiderman DB, et al. Cerebral metabolism and depression in patients with complex partial seizures. Arch Neurol 1992; 59: 617–23

    Article  Google Scholar 

  23. Robertson M. Mood disorders associated with epilepsy. In: McConnell HW, Snyder PJ, editors. Psychiatric comorbidity in epilepsy. Basic mechanisms, diagnosis, and treatment. Washington, DC: American Psychiatric Press, 1998: 132–67

    Google Scholar 

  24. Schmitz EB, Moriarty J, Costa DC, et al. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry 1997; 62: 458–63

    Article  PubMed  CAS  Google Scholar 

  25. Bench CJ, Frackowiak R, Dolan R. Changes in regional cerebral blood flow on recovery from depression. Psychol Med 1995; 25: 247–51

    Article  PubMed  CAS  Google Scholar 

  26. Standage KF, Fenton GW. Psychiatric symptom profiles of patients with epilepsy: a controlled investigation. Psychol Med 1975; 5: 152–60

    Article  PubMed  CAS  Google Scholar 

  27. Betts TA. A follow-up study of a cohort of patients with epilepsy admitted to psychiatric care in a English city. In: Harris P, Mawdsley C, editors. Epilepsy proceedings of the Hans Berger Centenary symposium. Edinburgh: Churchill Livingston, 1974: 326–38

    Google Scholar 

  28. Mendez MF, Doss RC, Taylor JL, et al. Depression in epilepsy: relationship to seizures and anticonvulsant therapy. J Nerv Ment Dis 1993; 181: 444–7

    Article  PubMed  CAS  Google Scholar 

  29. Landolt H. Some clinical electroencephalographical correlations in epileptic psychoses (twilight states) [abstract]. Electroencephalogr Clin Neurophysiol 1953; 5: 121

    Google Scholar 

  30. Landolt H. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorentz de Haas AM, editor. Lectures on epilepsy. Amsterdam: Elsevier, 1958: 91–133

    Google Scholar 

  31. Smith PF, Darlington CL. Neural mechanisms of psychiatric disturbances in patients with epilepsy. In: McConnell HW, Snyder PJ, editors. Psychiatric comorbidity in epilepsy. Basic mechanisms, diagnosis, and treatment. Washington, DC: American Psychiatric Press, 1998: 15–35

    Google Scholar 

  32. Trimble M. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1987; 19: 241–51

    Article  Google Scholar 

  33. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from electrical stimulation. Exp Neurol 1969; 25: 296–330

    Article  Google Scholar 

  34. Hermann BP, Whitman S. Psychosocial predictors of interictal depression. J Epilepsy 1989; 2: 231–7

    Article  Google Scholar 

  35. Brent D, Crumrine P, Varma R. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80: 909–17

    PubMed  CAS  Google Scholar 

  36. Barabas G, Matthews W. Barbiturate anticonvulsants as a cause of severe depression. Pediatrics 1988; 82: 284–5

    PubMed  CAS  Google Scholar 

  37. Dodrill CB. Behavioral effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble M, editors. Advances in neurology. Vol. 44. New York: Raven Press, 1991: 213–24

    Google Scholar 

  38. Ben-Menachem E, French J. Vigabatrin. In: Engel Jr J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia (PA): Lippincott-Raven Publishers, 1997: 1609–18

    Google Scholar 

  39. French J, Pellock J, Ferrendelli J, et al. Results of a multicenter, placebo-controlled, parallel study of vigabatrin (VGB, Sabril) in patients with focal epilepsy whose seizures are difficult to control [abstract]. Neurology 1993; 43 Suppl. 2: A307

    Google Scholar 

  40. Penry JK, Wilder BJ, Sachdeo RC, et al. Multicenter dose-response study of vigabatrin in brain and CSF of the rat. Brain Res 1980; 190: 288–92

    Google Scholar 

  41. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40(8): 1129–34

    Article  PubMed  CAS  Google Scholar 

  42. McElroy SL, Soutullo CA, Keck Jr PE, et al. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Clin Psychiatry 1997; 9(2): 99–103

    CAS  Google Scholar 

  43. Schaffer CB, Schaffer LC. Gabapentin for the treatment of bipolar disorder [letter]. Am J Psychiatry 1997; 154: 291

    PubMed  CAS  Google Scholar 

  44. Sokolski KN, Green C, Maris DE, et al. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999; 11(4): 217–22

    PubMed  CAS  Google Scholar 

  45. Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999; 60(4): 245–8

    Article  PubMed  CAS  Google Scholar 

  46. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000 Sep; 2 (3 Pt 2): 249–55

    Article  PubMed  CAS  Google Scholar 

  47. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88

    Article  PubMed  CAS  Google Scholar 

  48. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000; 12(1): 5–10

    PubMed  CAS  Google Scholar 

  49. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50

    Article  PubMed  CAS  Google Scholar 

  50. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998; 7: 207–11

    Article  PubMed  CAS  Google Scholar 

  51. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50(2–3): 245–51

    Article  PubMed  CAS  Google Scholar 

  52. McElroy SL, Suppes T, Keck Jr PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47(12): 1025–33

    Article  PubMed  CAS  Google Scholar 

  53. Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry 2001; 62 Suppl. 17: 60–3

    PubMed  Google Scholar 

  54. Leppik IE, Gram L, Deaton R, et al. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235–46

    Article  PubMed  CAS  Google Scholar 

  55. Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42

    Article  PubMed  CAS  Google Scholar 

  56. Meldrum BS, Chapman AG. Basic mechanisms of Gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40 Suppl. 9: S2–6

    Article  PubMed  CAS  Google Scholar 

  57. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be effective in the treatment of acute mania. J Clin Psychiatry 1999; 60(11): 759–62

    Article  PubMed  CAS  Google Scholar 

  58. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998; 10(4): 181–4

    PubMed  CAS  Google Scholar 

  59. Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4): 707-15

    Google Scholar 

  60. Joca SR, Skalisz LL, Beijamini V, et al. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 2000; 10(4): 223–8

    Article  PubMed  CAS  Google Scholar 

  61. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42(12): 1611–3

    Article  PubMed  CAS  Google Scholar 

  62. Harden CL, Pulver MC, Ravdin LD, et al. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000; 1: 93–9

    Article  PubMed  Google Scholar 

  63. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000; 47: 276–86

    Article  PubMed  CAS  Google Scholar 

  64. Edeh J, Toone BK. Antiepileptic therapy, folate deficiency and psychiatric morbidity: a general practice survey. Epilepsia 1985; 26: 434–40

    Article  PubMed  CAS  Google Scholar 

  65. Froscher W, Maier V, Laage M, et al. Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Clin Neuropharmacol 1995; 18: 165–82

    Article  PubMed  CAS  Google Scholar 

  66. Carney MWP, Chary TKN, Laundy M, et al. Red cell folate concentrations in psychiatric patients. J Affect Disord 1990; 19: 207–13

    Article  PubMed  CAS  Google Scholar 

  67. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999; 40 Suppl. 10: S2–20

    Article  PubMed  Google Scholar 

  68. Dell J. Social dimensions of epilepsy: stigma and response. In: Whitman S, Hermann PP, editors. Psychopathology in epilepsy: social perspectives. New York: Oxford University Press, 1986: 185–210

    Google Scholar 

  69. Hermann BP, Wyler AR. Depression, locus of control, and the effects of epilepsy surgery. Epilepsia 1989; 30(3): 332–8

    Article  PubMed  CAS  Google Scholar 

  70. Lefcourt HM. Locus of control. New York: Erlbaum, 1976

    Google Scholar 

  71. Katon W, VonKorff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76

    Article  PubMed  CAS  Google Scholar 

  72. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  73. Blumer D, Montouris G, Hermann B. Psychiatric morbidity in seizure patients on a neurodiagnostic monitoring unit. J Neuropsychiatry Clin Neurosci 1995; 7: 445–56

    PubMed  CAS  Google Scholar 

  74. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256–61

    PubMed  CAS  Google Scholar 

  75. Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86–90

    Article  PubMed  CAS  Google Scholar 

  76. Jabbari B, Dryan GE, Marsh EE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1

    Article  PubMed  CAS  Google Scholar 

  77. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54(8): 289–99

    PubMed  CAS  Google Scholar 

  78. DeVeaugh-Geis J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989; 25: 36–40

    Google Scholar 

  79. Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 1983; 3: 182–5

    Article  PubMed  CAS  Google Scholar 

  80. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 197–201

    PubMed  CAS  Google Scholar 

  81. Physician’s desk reference. Montvale (NJ): Medical Economics, 1999

  82. Edwards JG, Inman WHW, Wilton L, et al. Prescription-event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387–95

    Article  PubMed  CAS  Google Scholar 

  83. Physician’s desk reference. Montvale (NJ): Medical Economics, 2000

  84. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52(9): 1323–9

    Article  PubMed  CAS  Google Scholar 

  85. Prendiville S, Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 1993; 34(2): 381–4

    Article  PubMed  CAS  Google Scholar 

  86. Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia 1992; 33(3): 573–6

    Article  PubMed  CAS  Google Scholar 

  87. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34(3): 453–68

    Article  PubMed  CAS  Google Scholar 

  88. The Association of the British Pharmaceutical Industry (ABPI). Compendium of data sheets and summaries of product characteristics. London: Datapharm Publications, 1996

    Google Scholar 

  89. Ketter TA, Post RM, Parakh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995; 56(10): 471–5

    PubMed  CAS  Google Scholar 

  90. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 19 Suppl. 2: S37–53

    Article  Google Scholar 

  91. Levy RH, Mather GG. Metabolic enzymes and antiepileptic drug interactions. In: French J, Leppik I, Dichter MA, editors. Antiepileptic drug development. Advances in neurology. Vol. 76. Philadelphia (PA): Lippincott-Raven Publishers, 1998: 49–55

    Google Scholar 

  92. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41 Suppl. 1: S3–9

    Article  PubMed  CAS  Google Scholar 

  93. Kalinowsky LB, Kennedy F. Observations in electroshock therapy applied to the problems of epilepsy. J Nerv Ment Dis 1943; 98: 56–67

    Article  Google Scholar 

  94. Keller CH, Bernstein HJ. ECT as a treatment for neurologic illness. In: Coffey CE, editor. The clinical science of electroconvulsive therapy. Washington, DC: American Psychiatric Press, 1993: 183–210

    Google Scholar 

  95. Weiner RD, Coffey CE. Electroconvulsive therapy in the medical and neurologic patient. In: Stoudemeire A, Fogel BS, editors. Psychiatric care of the medical patient. New York: Oxford University Press, 1993: 207–24

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article, and the authors have no potential conflicts of interest that are directly relevant to its contents.

Author information

Authors and Affiliations

  1. Comprehensive Epilepsy Center, Weill Medical College of Cornell University, 525 East 68th Street, Room K-615, New York, New York, 10021, USA

    Cynthia L. Harden

  2. Department of Neurology and Psychiatry, Weill Medical College of Cornell University, New York, USA

    Martin A. Goldstein

Authors
  1. Cynthia L. Harden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin A. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia L. Harden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harden, C.L., Goldstein, M.A. Mood Disorders in Patients with Epilepsy. CNS Drugs 16, 291–302 (2002). https://doi.org/10.2165/00023210-200216050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200216050-00002

Keywords

Search

Navigation